July 6, 2020 11:08 AM EDT
News Briefing

Po­sei­da tees $150M IPO; Gilead sends HBV pro­gram back to Pre­ci­sion; New HIV da­ta from Mer­ck, Gilead

Jason Mast

Editor

→ Join­ing the long list of biotechs to aim for a large pan­dem­ic IPO, Po­sei­da Ther­a­peu­tics set terms for a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Up­dat­ed: Bio­gen makes cuts across its re­search unit, shift­ing fo­cus to ‘ex­ter­nal op­por­tu­ni­ties’

'No mir­a­cles': What Re­gen­eron's George Yan­copou­los re­al­ly thinks of AI

Chi­nese start­up be­gins first tri­al of in vi­vo CRISPR ther­a­py for blood dis­ease

RFK Jr. says he’ll di­vest in­ter­ests in CRISPR Ther­a­peu­tics if con­firmed for HHS chief

GLP-1s can cut the risk of Alzheimer’s. What does that mean for No­vo Nordisk?

sponsored

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

A service from the Financial Times